Current guidelines for chemoembolization for hepatocellular carcinoma: Room for improvement?

Jared A. White, Stephen H. Gray, Peng Li, Heather N. Simpson, Brendan M. McGuire, Devin E. Eckhoff, Ahmed Mohamed Kamel Abdel Aal, Souheil Saddekni, Derek A. Dubay – 18 May 2017 – Transarterial chemoembolization (TACE) is the most common oncologic therapy used according to the American Association for the Study of Liver Diseases (AASLD) guidelines established in 2005, revised in 2011. The purpose of this study was to determine how AASLD criteria for the management of hepatocellular carcinoma (HCC) have impacted TACE practice in the community.

Toward solving the etiological mystery of primary biliary cholangitis

Atsushi Tanaka, Patrick S.C. Leung, Howard A. Young, M. Eric Gershwin – 18 May 2017 – Primary biliary cholangitis (PBC) is considered a model autoimmune disease due to its signature anti‐mitochondrial antibody (AMA) autoantibody, female predominance, and relatively specific portal infiltration and cholestasis. The identification and cloning of the major mitochondrial autoantigens recognized by AMA have served as an immunologic platform to identify the earliest events involved in loss of tolerance.

The Braden Scale, A standard tool for assessing pressure ulcer risk, predicts early outcomes after liver transplantation

Vinay Sundaram, Jane Lim, Danielle M. Tholey, Sentia Iriana, Irene Kim, Vignan Manne, Nicholas N. Nissen, Andrew S. Klein, Tram T. Tran, Walid S. Ayoub, Barry Schlansky – 17 May 2017 – The Braden Scale is a standardized tool to assess pressure ulcer risk that is reported for all hospitalized patients in the United States per requirements of the Center for Medicare and Medicaid Services. Previous data have shown the Braden Scale can predict both frailty and mortality risk in patients with decompensated cirrhosis.

Subscribe to